Shopping Cart 0
Cart Subtotal
USD 0

Merkel Cell Carcinoma-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2000

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 4000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 6000
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Merkel Cell Carcinoma-Pipeline Review, H2 2017

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Merkel Cell Carcinoma-Pipeline Review, H2 2017, provides an overview of the Merkel Cell Carcinoma (Oncology) pipeline landscape.

Merkel cell carcinoma is a rare aggressive skin cancer that is at high risk of recurring and spreading (metastasizing) throughout the body. Risk factors for Merkel cell carcinoma include age, gender, light skin color, Ultraviolet exposure and immune suppression. Symptom includes painless nodule on skin. It usually starts on areas of skin exposed to the sun (face, neck, arms, and legs). Treatment includes chemotherapy, radiation therapy and surgery.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Merkel Cell Carcinoma-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Merkel Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Merkel Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Merkel Cell Carcinoma and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 13, 10 and 2 respectively. Similarly, the Universities portfolio in Phase I and Preclinical stages comprises 1 and 1 molecules, respectively.

Merkel Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct'sproprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The pipeline guide provides a snapshot of the global therapeutic landscape of Merkel Cell Carcinoma (Oncology).

The pipeline guide reviews pipeline therapeutics for Merkel Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Merkel Cell Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Merkel Cell Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Merkel Cell Carcinoma (Oncology)

Reasons to buy

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Merkel Cell Carcinoma (Oncology).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it'smost promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Merkel Cell Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Merkel Cell Carcinoma-Overview

Merkel Cell Carcinoma-Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Merkel Cell Carcinoma-Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Merkel Cell Carcinoma-Companies Involved in Therapeutics Development

Amgen Inc

Apcure SAS

BeiGene Ltd

Bristol-Myers Squibb Co

Checkpoint Therapeutics Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Genentech Inc

Immune Design Corp

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

NantKwest Inc

Novartis AG

OncoSec Medical Inc

Oncovir Inc

Ono Pharmaceutical Co Ltd

Philogen SpA

Tarveda Therapeutics Inc

Merkel Cell Carcinoma-Drug Profiles

APC-001-Drug Profile

atezolizumab-Drug Profile

avelumab-Drug Profile 60

bevacizumab-Drug Profile

cabozantinib s-malate-Drug Profile

Cellular Immunotherapy 1 for Oncology-Drug Profile

Cellular Immunotherapy 2 for Oncology-Drug Profile

CK-301-Drug Profile

G-100-Drug Profile

ipilimumab-Drug Profile

ipilimumab + nivolumab-Drug Profile

MAL-3101-Drug Profile

nivolumab-Drug Profile

pasireotide-Drug Profile

pasireotide ER-Drug Profile

pazopanib hydrochloride-Drug Profile

pembrolizumab-Drug Profile

PEN-221-Drug Profile 280

Poly-ICLC-Drug Profile

RO-7198457-Drug Profile

sapanisertib-Drug Profile

talimogene laherparepvec-Drug Profile

tavokinogene telseplasmid-Drug Profile

Teleukin-Drug Profile 30

tigilanol tiglate-Drug Profile

tislelizumab-Drug Profile

Vaccine to Target WT1 for Oncology-Drug Profile

Merkel Cell Carcinoma-Discontinued Products

Merkel Cell Carcinoma-Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development for Merkel Cell Carcinoma, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Top 10 Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Top 10 Molecule Types, H2 2017

Number of Products by Stage and Top 10 Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development for Merkel Cell Carcinoma, H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Merkel Cell Carcinoma-Pipeline by Amgen Inc, H2 2017

Merkel Cell Carcinoma-Pipeline by Apcure SAS, H2 2017

Merkel Cell Carcinoma-Pipeline by BeiGene Ltd, H2 2017

Merkel Cell Carcinoma-Pipeline by Bristol-Myers Squibb Co, H2 2017

Merkel Cell Carcinoma-Pipeline by Checkpoint Therapeutics Inc, H2 2017

Merkel Cell Carcinoma-Pipeline by Exelixis Inc, H2 2017

Merkel Cell Carcinoma-Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Merkel Cell Carcinoma-Pipeline by Genentech Inc, H2 2017

Merkel Cell Carcinoma-Pipeline by Immune Design Corp, H2 2017

Merkel Cell Carcinoma-Pipeline by Merck & Co Inc, H2 2017

Merkel Cell Carcinoma-Pipeline by Merck KGaA, H2 2017

Merkel Cell Carcinoma-Pipeline by Millennium Pharmaceuticals Inc, H2 2017

Merkel Cell Carcinoma-Pipeline by NantKwest Inc, H2 2017

Merkel Cell Carcinoma-Pipeline by Novartis AG, H2 2017

Merkel Cell Carcinoma-Pipeline by OncoSec Medical Inc, H2 2017

Merkel Cell Carcinoma-Pipeline by Oncovir Inc, H2 2017

Merkel Cell Carcinoma-Pipeline by Ono Pharmaceutical Co Ltd, H2 2017

Merkel Cell Carcinoma-Pipeline by Philogen SpA, H2 2017

Merkel Cell Carcinoma-Pipeline by Tarveda Therapeutics Inc, H2 2017

Merkel Cell Carcinoma-Discontinued Products, H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

Amgen Inc

Apcure SAS

BeiGene Ltd

Bristol-Myers Squibb Co

Checkpoint Therapeutics Inc

Exelixis Inc

F. Hoffmann-La Roche Ltd

Genentech Inc

Immune Design Corp

Merck & Co Inc

Merck KGaA

Millennium Pharmaceuticals Inc

NantKwest Inc

Novartis AG

OncoSec Medical Inc

Oncovir Inc

Ono Pharmaceutical Co Ltd

Philogen SpA

Tarveda Therapeutics Inc